Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PH Form 4 January 11, 2	IARMACEUTIC	CALS INC	2								
								OMB A	PPROVAL		
FORM	4 UNITED	STATES	TATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						3235-0287		
Check thi if no long						Number: Expires:	January 31,				
subject to Section 10 Form 4 or	6.	IENT OI	OWNERSHIP OF	Estimated burden hou response	urs per						
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).											
(Print or Type R	Responses)										
1. Name and Address of Reporting Person <u>*</u> Daly James M			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
			ACADIA PHARMACEUTICALS INC [ACAD]				(Check all applicable)				
(Last) (First) (Middle) 3611 VALLEY CENTRE DRIVE, SUITE 300			3. Date of Earliest Transaction(Month/Day/Year)01/07/2016					Director 10% Owner Officer (give title Other (specify below) below)			
							below) below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
SAN DIEGO	D, CA 92130						Person	wore than one R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities	Acquired, Disposed o	of, or Beneficia	lly Owned		
	2. Transaction Date (Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Prio	ce				
Reminder: Repo	ort on a separate line	for each cl	ass of sec	urities benef				ation of a	SEC 1474		
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.SEC 1474 (9-02)											
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

8 E

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	or Dispose (D)	Acquired (A) or Disposed of (D) (Instr. 3, 4,		(Month/Day/Year)		4)	S (,
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 28.73	01/07/2016		А	15,000		<u>(1)</u>	01/06/2026	Common Stock	15,000	

Reporting Owners

Reporting Owner Name / Address		Relationsh		
FB	Director	10% Owner	Officer	Other
Daly James M 3611 VALLEY CENTRE DRIVE SUITE 300 SAN DIEGO, CA 92130				
Signatures				
/s/ Elizabeth Carter, Attorney-in-Fact	01	/11/2016		
**Signature of Reporting Person		Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) $\frac{50\%}{\text{grant.}}$ of the shares subject to the Stock Option vest and become exercisable on each of the first and second anniversary of the date of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.